Antibiotic duration | Number of patients | Events (%) | Odds ratio (95% confidence interval) adjusted for age, gender and SAPS 3 scores | Odds ratio (95% confidence interval) adjusted for age, gender, SAPS 3 scores and length of stay |
---|---|---|---|---|
Piperacillin–tazobactam (n = 176) | ||||
Reference (i.e., use of other antibiotic than piperacillin–tazobactam or no antibiotic) | 65 | 13 (21.2) | 1 | 1 |
1–3 days | 17 | 6 (35.3) | 2.5 (0.8–8.0) | 2.3 (0.7–8.2) |
4–7 days | 29 | 11 (37.9) | 2.3 (0.8–6.1) | 2.2 (0.7–6.4) |
8–15 days | 34 | 9 (26.5) | 1.5 (0.6–4.1) | 1.5 (0.5–4.3) |
>15 days | 29 | 16 (55.2) | 4.7 (1.8–12.4)‡ | 1.7 (0.6–5.3) |
Ceftazidime (n = 171) | ||||
Reference (i.e., use of other antibiotic than ceftazidime or no antibiotic) | 99 | 22 (22.2) | 1 | 1 |
1–3 days | 13 | 0 | NA | NA |
4–7 days | 12 | 8 (66.7) | 1.7 (0.4–6.6) | 1.7 (0.4–7.4) |
8–15 days | 34 | 14 (41.2) | 2.6 (1.1–6.0)‡ | 1.7 (0.7–4.3) |
>15 days | 13 | 7 (53.8) | 3.4 (1.0–12.4)‡ | 0.7 (0.2–3.4) |
Ciprofloxacin (n = 128) | ||||
Reference (i.e., use of other antibiotic than ciprofloxacin or no antibiotic) | 78 | 7 (9) | 1 | 1 |
1–3 days | 18 | 2 (5.6) | 1.5 (0.3–7.9) | 2.0 (0.3–11.7) |
4–7 days | 10 | 0 | 0 | 0 |
8–15 days | 13 | 3 (23.1) | 2.7 (0.5–13.3) | 1.4 (0.2–850) |
>15 days | 9 | 5 (55.6) | 14.5 (2.8–75.0)‡ | 1.9 (0.2–15.6) |
Meropenem (n = 123) | ||||
Reference (i.e., use of other antibiotic than meropenem or no antibiotic) | 64 | 3 (4.7) | 1 | 1 |
1–3 days | 13 | 0 (0) | 0.0 | 0.0 |
4–7 days | 9 | 2 (5.6) | 4.9 (0.7–37.2) | 3.4 (0.4–30.2) |
8–15 days | 21 | 17 (81.0) | 104.5 (19.8–551.0)‡ | 79.1 (14.9–421.0)‡ |
>15 days | 16 | 5 (31.2) | 10.0 (2.0–49.5)‡ | 4.6 (1.7–32.2)‡ |
Amikacin (n = 148) | ||||
Reference (i.e., use of other antibiotic than amikacin or no antibiotic) | 87 | 10 (11.5) | 1 | 1 |
1–3 days | 41 | 7 (17.1) | 1.3 (0.4–4.2) | 0.7 (0.2–2.6) |
4–7 days | 13 | 1 (7.7) | 0.3 (0.03–3.0) | 0.1 (0.01–2.2) |
8–15 days | 7 | 1 (14.3) | 0.5 (0.05–5.1) | 0.1 (0.01–2.9) |
>15 days | 0 | 0 | 0.0 | 0.0 |